New combo therapy aims to shrink lymphoma with minimal side effects
NCT ID NCT06583837
First seen Mar 10, 2026 · Last updated Apr 30, 2026 · Updated 8 times
Summary
This study tests a two-step treatment for people with early-stage MALT lymphoma, a slow-growing cancer of the lymph nodes. First, patients take a targeted drug called orelabrutinib. Then, based on how well the tumor responds, they receive an ultra-low dose of radiation (4Gy). The goal is to control the disease while reducing side effects. The study involves 50 adults and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL, MARGINAL ZONE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.